InvestorsHub Logo
Followers 38
Posts 1440
Boards Moderated 0
Alias Born 03/07/2004

Re: geocappy1 post# 46792

Monday, 01/11/2010 10:52:03 AM

Monday, January 11, 2010 10:52:03 AM

Post# of 346282
geo, I like your postulation that a future partner for PPHM is actually specifying consultants to be hired, sumpin' like a port requiring an experienced pilot be put aboard boats about to enter a (safe) harbor. Good thought. Makes a lot of sense. We'll see. Someone already mentioned the DNA connection, which I have harped on for years. The following is from 1997, apparently after Garovoy was at the UCSF transplantation and immunology center (another DNA association):
BERKELEY, Calif.--(BW HealthWire)--May 28, 1997--Marvin R. Garovoy, MD, has joined XOMA Corporation (NASDAQ:XOMA) as director of clinical research, medical affairs. In this position he is helping the company move its products "from bench to bedside" by developing product and indication strategies, identifying products, choosing medical targets and designing clinical trials. He is also medical monitor for XOMA's hu1124 clinical trials and for the Neuprex(TM) partial hepatectomy trial. "It's great to have such a renowned transplant immunologist join our ranks," stated Patrick J. Scannon, MD, PhD, XOMA's chief scientific and medical officer. "Marv ...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News